These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28169231)

  • 1. Palbociclib: A new hope in the treatment of breast cancer.
    Palanisamy RP
    J Cancer Res Ther; 2016; 12(4):1220-1223. PubMed ID: 28169231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palbociclib: first global approval.
    Dhillon S
    Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
    DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
    Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
    Kish JK; Ward MA; Garofalo D; Ahmed HV; McRoy L; Laney J; Zanotti G; Braverman J; Yu H; Feinberg BA
    Breast Cancer Res; 2018 May; 20(1):37. PubMed ID: 29720233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
    Raphael J; Helou J; Pritchard KI; Naimark DM
    Eur J Cancer; 2017 Nov; 85():146-154. PubMed ID: 28930692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical and clinical development of palbociclib and future perspectives.
    de Dueñas EM; Gavila-Gregori J; Olmos-Antón S; Santaballa-Bertrán A; Lluch-Hernández A; Espinal-Domínguez EJ; Rivero-Silva M; Llombart-Cussac A
    Clin Transl Oncol; 2018 Sep; 20(9):1136-1144. PubMed ID: 29564714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
    Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Mori Y; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M
    Breast Cancer; 2019 Sep; 26(5):637-650. PubMed ID: 31127500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma.
    Altenburg JD; Farag SS
    Expert Opin Investig Drugs; 2015 Feb; 24(2):261-71. PubMed ID: 25494820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting breast cancer with CDK inhibitors.
    Mayer EL
    Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
    Hoste G; Punie K; Wildiers H; Beuselinck B; Lefever I; Van Nieuwenhuysen E; Han SN; Berteloot P; Concin N; Salihi R; Vergote I; Neven P
    Breast Cancer Res Treat; 2018 Aug; 171(1):131-141. PubMed ID: 29766363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
    Ham A; Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J
    Breast Cancer Res Treat; 2020 Aug; 183(1):107-116. PubMed ID: 32577940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
    Konecny GE
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
    Beaver JA; Amiri-Kordestani L; Charlab R; Chen W; Palmby T; Tilley A; Zirkelbach JF; Yu J; Liu Q; Zhao L; Crich J; Chen XH; Hughes M; Bloomquist E; Tang S; Sridhara R; Kluetz PG; Kim G; Ibrahim A; Pazdur R; Cortazar P
    Clin Cancer Res; 2015 Nov; 21(21):4760-6. PubMed ID: 26324739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperuricemia in 2 Patients Receiving Palbociclib for Breast Cancer.
    Bromberg DJ; Valenzuela M; Nanjappa S; Pabbathi S
    Cancer Control; 2016 Jan; 23(1):59-60. PubMed ID: 27009458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
    Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
    J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palbociclib (Ibrance) for metastatic breast cancer.
    Med Lett Drugs Ther; 2015 Aug; 57(1475):115-6. PubMed ID: 26262882
    [No Abstract]   [Full Text] [Related]  

  • 19. Palbociclib-Induced Posterior Reversible Encephalopathy Syndrome: A Previously Unreported Toxicity.
    Harrold EC; Peters NM; Williams LJ; Sui JS; McCaffrey JA
    J Oncol Pract; 2019 Feb; 15(2):119-121. PubMed ID: 30763200
    [No Abstract]   [Full Text] [Related]  

  • 20. Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.
    Owsley J; Jimeno A; Diamond JR
    Drugs Today (Barc); 2016 Feb; 52(2):119-29. PubMed ID: 27092341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.